In this video, Dr. Hu discusses why it can be critically important for some patients with urologic cancers to seek a second opinion on eligibility for robotic surgery.
In this video, Dr. Jim Hu speaks about his clinical expertise as a urologist specializing in the diagnosis and treatment of cancers of the urinary tract, including prostate, kidney, bladder and testicular cancers.
For more information on Dr. Hu, please visit his physician profile page.
In a 2014 modeling study published in Cancer, Gulati and colleagues predicted that if PSA screening continued at its current rate, 710,000 to 1.1 million men would be overdiagnosed between 2013 and 2025, but that 36,000 to 57,000 prostate cancer deaths would be prevented during that period.
Dr. Hu speaks about techniques & practical outcomes of various partial ablation procedures performed for men with prostate cancer, most notably the High Intensity Focused Ultrasound (HIFU) procedure, which is performed at Weill Cornell Medicine.
The incidence of metastatic prostate cancer in older men is rising after reaching an all-time low in 2011, according to new research from Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest a correlation between the increase and a change in prostate cancer screening guidelines recommending against routine prostate-specific antigen (PSA) testing.
Incidence of metastatic prostate cancer has increased among older men as PSA screening declines (With Dr. Jim C. Hu)
The incidence of metastatic prostate cancer appears to be rising in men aged 75 years or older, according to results of a SEER analysis published in JAMA Oncology.
This increase may be linked to the U.S. Preventive Services Task Force (USPSTF) 2008 recommendation against routine PSA screenings in men aged 75 years or older and the 2012 recommendation against routine PSA screening regardless of age.
Infectious complication rates following prostate biopsies continue to increase, despite decreased use of the procedures, a new study confirms.
Jim C. Hu, M.D., MPH, of Weill Cornell Medicine, and colleagues reported that the rates of infection within 30 days of prostate biopsy increased from 2.6% to 3.5% from 2011 to 2014 in New York State, based on data from patients of all ages and payment modalities. Complication rates were higher for transrectal than transperineal biopsies. Rates did not differ between initial and repeat biopsies.